Prognostic Stratification of Patients with Burkitt Lymphoma Using Serum beta 2-microglobulin Levels
- Authors
- Kim, HD[Kim, Hyung-Don]; Cho, H[Cho, Hyungwoo]; Kim, S[Kim, Shin]; Lee, K[Lee, Kyoungmin]; Kang, EH[Kang, Eun Hee]; Park, JS[Park, Jung Sun]; Park, CS[Park, Chan-Sik]; Huh, J[Huh, Jooryung]; Ryu, JS[Ryu, Jin Sook]; Lee, SW[Lee, Sang-Wook]; Yoon, DH[Yoon, Dok-Hyun]; Kim, SJ[Kim, Seok Jin]; Ko, YH[Ko, Young Hyeh]; Kim, WS[Kim, Won Seog]; Suh, C[Suh, Cheolwon]
- Issue Date
- Jul-2021
- Publisher
- KOREAN CANCER ASSOCIATION
- Keywords
- Burkitt lymphoma; beta 2-microglobulin; Prognosis; Risk stratification
- Citation
- CANCER RESEARCH AND TREATMENT, v.53, no.3, pp.847 - 856
- Indexed
- SCIE
SCOPUS
KCI
OTHER
- Journal Title
- CANCER RESEARCH AND TREATMENT
- Volume
- 53
- Number
- 3
- Start Page
- 847
- End Page
- 856
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/89439
- DOI
- 10.4143/crt.2020.1060
- ISSN
- 1598-2998
- Abstract
- Purpose We aimed to investigate the prognostic value of serum beta 2-microglobulin for patients with Burkitt lymphoma (BL) and to propose a risk-stratifying classification system. Materials and Methods A prospective registry-based cohort study of BL patients treated with dose-intensive or effective dose-adjusted chemotherapies (n=81) was conducted. Survival outcomes were compared based on previously reported risk groups and/or serum beta 2-microglobulin levels. A risk-stratifying classification system incorporating serum beta 2-microglobulin levels was proposed and validated in an independent validation cohort (n=60). Results The median age was 47 years, and 57 patients (70.4%) were male. Patients with high serum beta 2-microglobulin levels (> 2 mg/L) had significantly worse progression-free survival (PFS) and overall survival (OS) (p < 0.01 for both). Serum beta 2-microglobulin levels further stratified patients in the low-risk and high-risk groups in terms of PFS (p=0.010 and p=0.044, respectively) and OS (p=0.014 and p=0.026, respectively). Multivariate analyses revealed that a high serum beta 2-microglobulin level (> 2 mg/L) was independently associated with a shorter PFS (hazards ratio [HR], 3.56; p=0.047) and OS (HR, 4.66; p=0.043). The new classification system incorporating the serum beta 2-microglobulin level allowed the stratification of patients into three distinct risk subgroups with 5-year OS rates of 100%, 89.5%, and 62.5%. In an independent cohort of BL, the system was validated by stratifying patients with different survival outcomes. Conclusion Serum beta 2-microglobulin level is an independent prognostic factor for BL patients. The proposed beta 2-microglobulin-based classification system could stratify patients with distinct survival outcomes, which may help define appropriate treatment approaches for individual patients.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.